组蛋白甲基化：肿瘤治疗的新靶标  

Histone methylation： a new target to cancer therapy

作　　者：韩会丹(综述)[1] 马旭东(审校)[1] 

机构地区：[1]福建医科大学附属漳州市医院血液科,漳州350004

出　　处：《白血病．淋巴瘤》2011年第4期254-256,共3页Journal of Leukemia & Lymphoma

基　　金：卫生部科学研究基金福建卫生教育联合攻关计划（wkj2008-2-55）;福建医科大学科学研究发展专项基金计划（FZS08018）;漳州市科学研究发展计划基金（Z07014）

摘　　要：暴露在核小体表面的N-末端尾部可发生共价修饰，这些共价修饰可以影响组蛋白和DNA结合的紧密程度，从而影响DNA的表达，被称之为“组蛋白密码”。近来大量的研究表明，组蛋白末端的赖氨酸和精氨酸残基的异常甲基化与肿瘤的发生、发展、预后有着密切的关系。应用组蛋白甲基转移酶／去甲基转移酶抑制剂调控组蛋白的甲基化水平，能够抑制肿瘤细胞的生长并诱导凋亡。The N-terminal tail of histone exposed to the surface of nucleosomes could be covalently modificated. Chromatin condensation is controlled by modification of the amino acid residues in the histone tails. The different modifications of amino acids in histones, and their combinations, have been suggested to be the histone code＇ . It effects functionally on the nuclear processes and DNA expression. Recently, a large number of study show that aberrant methylations in lysine and arginine side chains of histone is related to carcinogenesis and development. Histone methyltransferase/demethylases inhibitors can regulate the histone methylation which inhibit cell growth and induce apoptosis in tumor cells.

关 键 词：甲基化 甲基转移酶类 肿瘤 治疗 

分 类 号：R735.8[医药卫生—肿瘤]